Healthcare Cost Arbitrage
as an Alternative Asset Class
Institutional-grade investment strategy delivering 23% IRR with low correlation to public markets. Purpose-built for family offices seeking uncorrelated alpha in recession-resistant healthcare infrastructure.
Backtest average return
To public equity markets
Non-discretionary spending
Recovery cycle timeline
Investment Thesis
Healthcare cost arbitrage represents a structural market inefficiency in the $4.5T U.S. healthcare economy. Our platform identifies, validates, and monetizes these opportunities with institutional rigor.
Service Lines
Comprehensive support for family offices across investment evaluation, portfolio construction, and operational diligence.
Track Record
5-year historical performance across 200+ employer clients and $8.2B in validated EBITDA opportunities.
Outperforms private equity (18.2%), venture capital (21.1%), and real estate (11.3%) over same period.
True portfolio diversification. Healthcare spend is non-discretionary and recession-resistant.
Cryptographically verified evidence receipts across 200+ employers. 95.2% DQ pass rate.
Faster liquidity than traditional alternatives. 62-85% average recovery rate with evidence.